patients at high risk for cardiovascular events clinical trials results

candesartan versus placebo
SCOPE, 2003	candesartan, 8–16 mg once daily (target 160/90) versus placebo	patients aged 70–89 years, with systolic blood pressure 160– 179 mmHg, and/or diastolic blood pressure 90–99 mmHg, and a Mini Mental State Examination (MMSE) test score > 24	double-blind Follow-up duration: 3.7 y (mean) 15 countries
enalapril versus placebo
CAMELOT (enalapril), 2004	Enalapril 20mg daily versus Placebo	patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg	double blind Follow-up duration: 24 months
LCZ696 versus placebo
Ruilope, 2010	LCZ696 for 8 weeks versus placebo	patients with mild to moderate hypertension	double blind Follow-up duration: 8 weeks 18 countries
losartan versus atenolol
LIFE, 2002	losartan versus atenolol	patients aged 55–80 years, with previously treated or untreated hypertension (sitting blood pressure 160–200/95–115 mm Hg) and ECG signs of LVH.	Double blind Follow-up duration: 4.8 y (mean) USA, Europe
losartan versus placebo
RENAAL, 2001	lLosartan 50 to 100 mg once daily versus placebo	patients with type 2 diabetes and nephropathy	double-blind Follow-up duration: 3.4 years
perindopril versus placebo
EUROPA, 2003	perindopril 8 mg once daily versus placebo	low-risk patients with stable coronary heart disease and no apparent heart failure	double blind Follow-up duration: 4.2y
quinapril versus placebo
QUIET, 2001	Quinapril 20mg one daily versus Placebo	patients with angiographic evidence of coronary artery disease without systolic leftventricular dysfunction	double blind Follow-up duration: 27 months United States, Canada, Europe
ramipril versus placebo
HOPE, 2000	ramipril 10 mg once per day orally versus placebo	high-risk patients (55 years of age or older) with evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure	double blind Follow-up duration: 5 y
telmisartan versus placebo
TRANSCEND, 2008 NCT00153101	telmisartan 80 mg/day versus placebo	high-risk patients intolerant to angiotensin-converting enzyme inhibitors	double blind Follow-up duration: median 56 months (IQR 51-64) 40 countries
PROPHESS, 2008 NCT00153062	telmisartan 80 mg daily versus placebo	patients who recently had an ischemic stroke	double blind Follow-up duration: 2.5 y 35 countries
telmisartan versus ramipril
ONTARGET (telmisartan alone), 2008 NCT00153101	telmisartan 80mg daily versus ramipril 10 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage	double blind Follow-up duration: 4.7y 40 countries
telmisartan + ramipril versus ramipril
ONTARGET (association vs ramipril), 2008 NCT00153101	telmisartan 80mg + ramipril 10mg daily versus ramipril 10 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage	double blind Follow-up duration: 4.7y 40 countries
telmisartan + ramipril versus telmisartan
ONTARGET (association vs telmisartan), 2008 NCT00153101	telmisartan 80mg + ramipril 10mg daily versus telmisartan 80 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage	double blind Follow-up duration: 4.7y 40 countries
trandolapril versus placebo
PEACE, 2004 NCT00000558	Trandolapril at a target dose of 4 mg per day versus Placebo	patients with stable coronary artery disease and normal or slightly reduced left ventricular function	Double blind Follow-up duration: median 4.8 y United States, Canada, Italy
valsartan versus amlodipine
VALUE, 2004 NCT00129233	valsartan based regimen versus amlodipine based regimen	patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events	Double blind Follow-up duration: 4.2 y (mean) 31 countries